Lantern Pharma Inc

Lantern Pharma operates with a capital structure that is entirely equity-funded, as it has no long-term debt and a debt-to-equity ratio of 0.0. The company's liquidity position is strong, with a current ratio of 9.98, indicating that it has significantly more current assets than current liabilities. However, the company's liquidity is constrained by negative operating and free cash flows of -$3.07 million and -$5.44 million, respectively, which suggest ongoing cash burn.

Profitability metrics for Lantern Pharma are negative, with a return on equity (ROE) of -15.21% and a return on assets (ROA) of -13.69%, both of which are below the industry median for biotechnology firms. The company reported a net loss of $5.44 million and an operating loss of $5.73 million, indicating that it is not yet generating positive returns for shareholders.

The company's revenue is not disclosed in the available data, and no specific geographic or segment breakdown is provided. However, the absence of revenue concentration data suggests that Lantern Pharma may be in an early stage of development, with limited commercial operations. The company's business model is currently centered on research and development, with no disclosed revenue-generating products or services.

Looking ahead, Lantern Pharma is expected to continue experiencing negative cash flows and losses in the near term. The company's outlook for the current fiscal year is not explicitly provided, but the continuation of negative operating and free cash flows suggests that it will require ongoing capital to fund operations. The absence of dilution flags and the low dilution risk assessment indicate that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders.

Recent events related to Lantern Pharma include the publication of its latest financial results, which show continued losses and negative cash flows. No recent filings or transcripts are available that provide additional insight into the company's strategic direction or operational progress.

Operating income +28,7% YoY; Net income +30,6% YoY.

• ▍Operating income +28,7% YoY
• ▍Net income +30,6% YoY
• ▍Free cash flow +30,7% YoY

Operating income +16,0% YoY; Net income +7,3% YoY.

• ▍Operating income +16,0% YoY
• ▍Net income +7,3% YoY
• ▍Free cash flow +7,3% YoY

Operating income +14,0% YoY; Net income +12,7% YoY.

• ▍Operating income +14,0% YoY
• ▍Net income +12,7% YoY
• ▍Free cash flow +12,8% YoY

Operating income +16,7% YoY; Net income +16,6% YoY.

• ▍Operating income +16,7% YoY
• ▍Net income +16,6% YoY
• ▍Free cash flow +16,6% YoY

Operating income -$5.9M.

• ▍Operating income -$5.9M

Operating income -$5.2M.

• ▍Operating income -$5.2M

Operating income -$5.4M.

• ▍Operating income -$5.4M

Operating income -$5.7M.

• ▍Operating income -$5.7M

Operating income +19,1% YoY; Net income +17,6% YoY.

• ▍Operating income +19,1% YoY
• ▍Net income +17,6% YoY
• ▍Free cash flow +17,7% YoY

Operating income −24,3% YoY; Net income −30,2% YoY.

• ▍Operating income −24,3% YoY
• ▍Net income −30,2% YoY
• ▍Free cash flow −30,1% YoY

Operating income −23,9% YoY; Net income −11,9% YoY.

• ▍Operating income −23,9% YoY
• ▍Net income −11,9% YoY
• ▍Free cash flow −11,8% YoY

Operating income −15,6% YoY; Net income −15,3% YoY.

• ▍Operating income −15,6% YoY
• ▍Net income −15,3% YoY
• ▍Free cash flow −15,4% YoY